-Study highlights dual targeting action, demonstrating significant therapeutic potential for treating myotonic dystrophy type 1 (DM1) across a variety of disease severities – VALENCIA, Spain, Oct. 16, 2024 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.